

Agreement 20: Antimicrobial Stewardship and Novel Antibiotic Access Program

Parties: BioPharma Innovations and United Kingdom National Health Service **Country:** United Kingdom **Disease Area:** Multi-Drug Resistant Bacterial Infections **Agreement Overview:** This pioneering agreement addresses the dual challenges of antimicrobial resistance and limited commercial viability of new antibiotics. Creating a novel subscription-based model decoupled from sales volume, this contract ensures access to critical reserve antibiotics while incentivizing appropriate stewardship. The agreement covers approximately 65 UK hospitals and creates sustainable funding for novel antimicrobials effective against priority pathogens including CRE, MRSA, and resistant Pseudomonas.

Financial Structure:

- Subscription model: £9.2 million annual payment for guaranteed access to portfolio of 3 novel antibiotics regardless of usage volume
- Population coverage: Ensures availability for approximately 45 million UK residents
- Tiered availability approach:
 - Tier 1: Unrestricted access for life-threatening infections with documented resistance
 - Tier 2: Infectious disease consultation required for empiric therapy
 - Tier 3: Approval by antimicrobial stewardship committee required
- Value assessment: Initial value set at £18.5 million based on modeled lives saved and resistance prevention
- Stewardship incentive: £2.5 million annual fund for hospitals demonstrating optimal prescribing practices
- Research component: £3.8 million allocated for resistance surveillance and clinical effectiveness studies
- Usage thresholds: Review mechanisms if utilization significantly exceeds or falls below projections
- Manufacturing guarantee: Minimum production volume ensured regardless of clinical usage
- Supply chain security: Dedicated UK stockpile maintained for emergency scenarios

Duration: 10 years with comprehensive review at 3-year intervals **Special Provisions:**

- Antimicrobial stewardship program implementation in all participating hospitals
- Rapid diagnostic testing infrastructure for pathogen identification
- Centralized resistance surveillance network with mandatory reporting
- Clinical decision support systems integration in electronic prescribing
- Specialist infectious disease consultation service (in-person and telehealth)
- Mandatory outcome tracking for all novel antibiotic use
- Regular prescriber education on optimal antimicrobial use

- Emergency access protocol for critically ill patients
- Research protocol for real-world effectiveness data collection
- Development pipeline support for next-generation antimicrobials